Pharmacological management of breathlessness in advanced disease

Abstract Dyspnoea is one of the most distressing symptoms experienced by patients with life-limiting illnesses; when not relieved by disease management strategies it is termed 'refractory dyspnoea' and global palliative approaches are required. The focus of care shifts from prolonging survival to reducing symptoms, increasing function, and improving quality of life. Numerous pharmacological and non-pharmacological interventions can achieve these goals, though the level of evidence supporting their use varies. This narrative review provides a summary of pharmacological options for the management of refractory breathlessness, with a focus on those options with adequate supporting data; oxygen therapy is also considered as a potentially viable palliative measure. Currently available evidence is provided, highlighting areas for further investigation of selected approaches. The agents with adequate current evidence warranting inclusion as current 'best practices' are: oxygen, opioids, psychotropic drugs, inhaled frusemide, and Heliox 28.

[1]  A. Abernethy,et al.  Oxygen use--patients define symptomatic benefit discerningly. , 2007, Journal of pain and symptom management.

[2]  A. Abernethy,et al.  Prescribing palliative oxygen: a clinician survey of expected benefit and patterns of use , 2005, Palliative medicine.

[3]  P. Hernandez,et al.  Physician Practices for Prescribing Supplemental Oxygen in the Palliative Care Setting , 2004, Journal of palliative care.

[4]  A. Earnest,et al.  Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[5]  S. Ahmedzai,et al.  A double-blind, randomised, controlled Phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion , 2004, British Journal of Cancer.

[6]  J. Berrill,et al.  Morphine for management of refractory dyspnoea , 2003, BMJ : British Medical Journal.

[7]  A. Abernethy,et al.  Morphine for management of refractory dyspnoea , 2003, BMJ : British Medical Journal.

[8]  A. Abernethy,et al.  Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea , 2003, BMJ : British Medical Journal.

[9]  J. Higgins,et al.  A systematic review of the use of opioids in the management of dyspnoea , 2002, Thorax.

[10]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[11]  S. Booth,et al.  The shuttle walking test: a reproducible method for evaluating the impact of shortness of breath on functional capacity in patients with advanced cancer , 2001, Thorax.

[12]  Z. Nahas,et al.  Functional impairment in COPD patients: the impact of anxiety and depression. , 2000, Psychosomatics.

[13]  G. Guyatt,et al.  Appropriateness of domiciliary oxygen delivery. , 2000, Chest.

[14]  J. Baird,et al.  Descriptors of breathlessness in healthy individuals: distinct and separable constructs. , 2000, Chest.

[15]  T. Nishino,et al.  Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. , 2000, American journal of respiratory and critical care medicine.

[16]  Y. Nishiwaki,et al.  Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale , 2000, British Journal of Cancer.

[17]  Murray D. Altose,et al.  Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. , 1999, American journal of respiratory and critical care medicine.

[18]  J. Gorman,et al.  Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders. , 1995, The American journal of psychiatry.

[19]  A. Rubinfeld,et al.  Chronic lung diseases and the perception of breathlessness: a clinical perspective. , 1994, The European respiratory journal.

[20]  R. Light,et al.  Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. , 1993, Chest.

[21]  E. Bruera,et al.  Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. , 1992, Journal of pain and symptom management.

[22]  K. Chung,et al.  Loop diuretics and asthma. , 1992, Pulmonary pharmacology.

[23]  K. Chung,et al.  Inhaled furosemide inhibits cough induced by low chloride content solutions but not by capsaicin. , 1990, The American review of respiratory disease.

[24]  R. M. Refini,et al.  Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. , 1989, The New England journal of medicine.

[25]  F. Eldridge,et al.  Buspirone, an anxiolytic drug that stimulates respiration. , 1989, The American review of respiratory disease.

[26]  F. Pucino,et al.  Effects of Alprazolam on Respiratory Drive, Anxiety, and Dyspnea in Chronic Airflow Obstruction: A Case Study , 1989, Pharmacotherapy.

[27]  M. Robuschi,et al.  PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION BY INHALED FRUSEMIDE , 1988, The Lancet.

[28]  G. Man,et al.  Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. , 1986, Chest.

[29]  P. Leggat,et al.  The Response of the Breathless Patient Treated with Diazepam , 1983, The British journal of clinical practice.

[30]  T. Hedner,et al.  The neuropharmacology of respiratory control. , 1982, Pharmacological reviews.

[31]  A. Woodcock,et al.  Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. , 1981, British medical journal.

[32]  T. V. Santiago,et al.  Effects of morphine on ventilatory response to exercise. , 1979, Journal of applied physiology: respiratory, environmental and exercise physiology.

[33]  T. V. Santiago,et al.  Control of breathing during methadone addiction. , 1977, The American journal of medicine.

[34]  P. Macklem,et al.  Effect of meperidine on occlusion pressure responses to hypercapnia and hypoxia with and without external inspiratory resistance. , 1976, The American review of respiratory disease.

[35]  R. Mccullough,et al.  Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. , 1975, The New England journal of medicine.

[36]  J. Howell,et al.  Disproportionately severe breathlessness in chronic bronchitis. , 1969, The Quarterly journal of medicine.

[37]  J. Eckenhoff,et al.  The effects of narcotics and antagonists upon respiration and circulation in man. A review. , 1960, Clinical pharmacology and therapeutics.

[38]  L. Cerchietti,et al.  Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. , 2006, Journal of pain and symptom management.

[39]  Miriam J. Johnson,et al.  The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. , 2004, Respiratory medicine.

[40]  J. Smoller,et al.  Sertraline effects on dyspnea in patients with obstructive airways disease. , 1998, Psychosomatics.

[41]  D. Georgopoulos,et al.  Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. , 1993, Respiration; international review of thoracic diseases.

[42]  D. Rapoport,et al.  Effects of buspirone on sleep and respiration. , 1990, The American review of respiratory disease.

[43]  M. Robuschi,et al.  Inhaled frusemide is highly effective in preventing ultrasonically nebulised water bronchoconstriction. , 1989, Pulmonary pharmacology.

[44]  K. Murphy,et al.  Diazepam in the treatment of dyspnoea in the 'Pink Puffer' syndrome. , 1980, The Quarterly journal of medicine.